Phase 3 Preliminary analysis ...

Phase 3

Preliminary analysis of palonosetron (MGI Pharma, Inc., Bloomington, MN and Helsinn Heathcare SA, Lugano, Switzerland), an agent perform the operations indicated ined to prevent chemotherapy-induced nausea and vomiting, met targeted efficacy endpoints, a percentage of exposes who did not experience vomiting or receive liberation medication in the 24-hour period after receiving chemotherapy. The randomized, double-blind Phase 3 trial was mannersed at more than 130 medical center across North America and Europe and involved approximately 1800 make submissives Additionally, the preliminary analysis